• Flubendazole Workflows for Autophagy Research

  2026-09-04

  Learn how to deploy Flubendazole as a DMSO-soluble autophagy activator in cell-based assays, with practical controls for solubility, viability, and autophagy flux. A reference-driven workflow also shows how to connect autophagy measurements with glutamine metabolism without overstating disease-specific conclusions.

• Repurposed Vitamins Against SARS-CoV-2: Docking Evidence

  2026-09-04

  The 2022 Journal of Molecular Modeling study used virtual screening, molecular docking, and molecular dynamics to evaluate vitamins against the SARS-CoV-2 spike receptor-binding domain and 3CL protease. Its main contribution is a target-specific prioritization of compounds for viral entry and replication studies, while its computational design also highlights the need for biochemical and cellular validation.

• Docosahexaenoic Acid in POCD Lipid Research

  2026-09-03

  A practical guide to using Docosahexaenoic Acid (DHA) to investigate hippocampal lipid remodeling, synaptic injury, oxidative stress, and cognition. The workflow translates a rat cardiopulmonary-bypass study into actionable decisions for formulation, assay selection, controls, and troubleshooting in neuroprotection research.

• EdU Imaging Kits (488) for HAUS1 Phenotyping

  2026-09-03

  EdU Imaging Kits (488) connect S-phase DNA synthesis measurement with functional HAUS1 studies in hepatocellular carcinoma. This guide focuses on experimental design, orthogonal validation, and interpretation beyond conventional cell proliferation assays.

• Synthetic DEFB1 mRNA Limits Cryptosporidium Infection

  2026-09-02

  The reference study shows that synthetic DEFB1 mRNA can increase β-defensin 1 protein in human intestinal cells and reduce Cryptosporidium parvum burden in vitro. Its design links transient host-gene induction with a measurable anti-parasitic phenotype, while also illustrating how EGFP-based transfection validation can support intestinal infection research.

• RNAi Maps Rab11a-Linked SARS-CoV-2 Release Factors

  2026-09-02

  Kerr et al. used a two-timepoint, arrayed druggable-genome RNA interference screen to examine host factors acting across the SARS-CoV-2 replication and reinfection cycle, including late particle production and release. The study identifies Rab11a-associated vesicular transport as a conserved proviral pathway and provides pharmacological evidence that CDK9 inhibitor-73 can suppress viral release, while also defining important limits for interpreting host-directed antiviral targets.

• PSPro Maps Spatial Proteomes at Single-Cell Resolution

  2026-09-01

  Mao and colleagues introduce PSPro, a proximity-labeling workflow that captures proteomes from multiple antibody-defined cell types directly within one tissue slice. By combining optimized antibody-targeted biotinylation with affinity purification and optional laser microdissection, the study resolves spatial proteome heterogeneity while reducing the throughput and sampling compromises of conventional LMD-MS and imaging approaches.

• RNAi Screen Maps SARS-CoV-2 Release Factors

  2026-09-01

  Kerr et al. used an arrayed, druggable-genome RNA interference screen to examine host factors across the SARS-CoV-2 replication and reinfection cycle, rather than focusing mainly on early replication. The study identifies Rab11a-linked vesicular transport as a conserved proviral pathway and shows that pharmacological CDK9 inhibition can reduce viral release, supporting further investigation of host-directed antiviral strategies.

• Programmable 3D Gold Nanoclusters for SERS

  2026-08-31

  The reference study presents a polymer pen lithography route for constructing ordered three-dimensional gold nanoparticle cluster arrays on patterned polyethylenimine structures. By adjusting lithographic pattern dimensions and architecture, the authors obtained strong SERS enhancement together with reproducibility, addressing a central trade-off between nanoscale control, fabrication simplicity, and substrate uniformity.

• Axitinib (AG 013736): VEGFR Research Guide

  2026-08-31

  Axitinib, also called AG 013736, is a potent oral VEGFR1/2/3 tyrosine kinase inhibitor for angiogenesis and cancer biology research. Supplier-reported biochemical and cellular benchmarks show subnanomolar VEGFR activity, while mouse xenograft data support its use in tumor growth inhibition studies.

• In Vitro Drug Response: Viability, Growth, and Death

  2026-08-30

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to clarify how anticancer drugs affect proliferation and cell death. Its central practical implication is that drug-response studies should treat these endpoints as complementary, time-dependent measurements rather than interchangeable readouts.

• Antiepileptic Drugs and Human Aromatase Inhibition

  2026-08-29

  Jacobsen and colleagues compared 12 antiepileptic drugs in a human CYP19 microsomal assay and identified several compounds, including lamotrigine, that reduced aromatase activity. The study provides a mechanistic screening framework for interpreting possible endocrine effects while emphasizing that in vitro inhibition does not by itself establish clinical hormone disruption.

• Bsa I (RNase-free): Practical DNA Cleavage Guide

  2026-08-28

  Bsa I (RNase-free) supports sequence-directed DNA cleavage for gene cloning, DNA manipulation, and other molecular biology research workflows where RNA preservation is important. It is intended for controlled research use, not diagnostic or medical procedures, and should be handled with an RNase-controlled workflow.

• Chlorin e6: Practical PDT Workflows

  2026-08-28

  Chlorin e6 combines strong light-triggered ROS production with flexible delivery options, from cancer-cell assays to antibacterial silk fibroin scaffolds. This practical guide translates Ce6 photosensitizer chemistry into reproducible workflows, optimization logic, and troubleshooting strategies.

• How Impending Cell Death Creates Prometastatic States

  2026-08-27

  Conod, Silvano, and Ruiz i Altaba show that tumor cells surviving an impending-death experience can become stable prometastatic cells, termed PAMEs, rather than simply returning to a baseline state. Their work connects ER-stress signaling, nuclear reprogramming, and a cytokine-mediated interaction with neighboring PIM cells, offering a mechanistic framework for how treatment-associated stress may reshape the metastatic ecosystem.

8483 records 1/566 page Next 12345 下5页 Last page